Starting next month, the maximum reimbursement prices for two acetaminophen suspension formulations will be increased by over 50%. The price hike follows the government’s decision to implement measures aimed at encouraging pharmaceutical companies to expand volume of acetaminophen production. Currently, there is a continuous demand for the drugs due to a high number of patients with influenza and the common cold.

Following the drug price increase for pill-type acetaminophen monotherapy last year, suspension formulations have now joined the list of drug receiving pricing increases within a year. The drug pricing increase in acetaminophen suspension formulations is expected to lead to an annual increase by